ChemoCentryx Inc., a Mountain View, Calif.-based developer of oral drugs for autoimmune diseases, inflammatory diseases and oncology, has raised $29.84 million in Series D funding, according to a regulatory filing. Glaxo Group Ltd. was joined by return backers like Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.